Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinary tract symptoms of benign prostatic hyperplasia after 8 weeks of daily administration of 10 mg BID.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Vardenafil Dihydrochloride

Criteria

Inclusion Criteria:

• Males 45 to 64 years of age

• Lower urinary tract symptoms > 6 months

• International Prostate Symptom Score > 12

Exclusion Criteria:

• Prostate Specific Antigen > 3 ng/ml

• Residual urine volume > 150 m

• History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months

• Nitrate use

• Other exclusion criteria apply acc. to Summary of Product Characteristics